Business Context and Reporting Period
Company: Moleculin Biotech, Inc. (MBRX)
Filing Type: Form 8-K (Current Report)
Date of Report: February 18, 2026
Reporting Period: Single event date (February 18, 2026)
Business Context: The filing serves as a Regulation FD disclosure to distribute a corporate investor presentation dated February 2026. The presentation is attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disseminate an external presentation rather than a financial statement containing audited or unaudited financial data.
Material Changes
No material changes to financial position or operations are detailed within the text of this 8-K. The filing solely announces the availability of the attached investor presentation.
Guidance, Outlook, and Risks
Management Commentary: The Company is furnishing an investor presentation to the market.
Legal Status of Information: The information contained in Item 7.01 and Exhibit 99.1 is being "furnished" and shall not be considered "filed" under the Securities Exchange Act of 1934. It will not be incorporated by reference into other filings unless specifically identified.
Risks and Contingencies: No specific risks or contingencies are disclosed in the text of this filing.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation) for specific financial data, guidance, and strategic updates, as the 8-K text itself contains no such figures.
- Verify the trading symbol (MBRX) and exchange (NASDAQ) for current market data.
- Note that the information in the presentation is not legally "filed" and may not be incorporated by reference in future SEC documents.
- Confirm the date of the presentation (February 2026) to ensure data currency relative to the filing date.